Matinas BioPharma Holdings, Inc. Logo

Matinas BioPharma Holdings, Inc.

Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.

MTNB | US

Overview

Corporate Details

ISIN(s):
US5768101058
LEI:
Country:
United States of America
Address:
1545 ROUTE 206 SOUTH, 7921 BEDMINSTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel products to address unmet medical needs. The company's core technology is its proprietary Lipid Nano-Crystal (LNC) platform, which enables the safe, oral, and intracellular delivery of small molecules, nucleic acids, and other therapeutics. Its lead product candidate, MAT2203, is an oral formulation of the anti-fungal drug amphotericin B. In addition to infectious diseases, Matinas is pursuing discovery programs using its LNC platform for applications in oncology and inflammation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Matinas BioPharma Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matinas BioPharma Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matinas BioPharma Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8
PALISADE BIO, INC. Logo
Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.
United States of America
PALI
PALVELLA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
United States of America
PVLA
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea
222110
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA
Pelthos Therapeutics Inc. Logo
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
United States of America
PTHS
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany
PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea
304840

Talk to a Data Expert

Have a question? We'll get back to you promptly.